Brought to you by 
Ionix and Reckitt Benckiser Healthcare develop pain drugs
27 Apr 2021
Executive Summary
Analgesics biotech Ionix Pharmaceuticals Ltd. and Reckitt Benckiser Healthcare (mostly OTC and personal care, part of the large household cleaners company Reckitt Benckiser PLC) will ally to develop three Ionix pain candidates that are based on the mu-opioid agonist buprenorphine.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- Co-Promotion
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Ionix and Reckitt Benckiser Healthcare develop pain drugs
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice